Catalent Inc (NASDAQ:CTLT) Given Average Rating of “Hold” by Analysts
Shares of Catalent Inc (NASDAQ:CTLT) have been assigned an average rating of “Hold” from the seven brokerages that are currently covering the stock. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $28.67.
Several equities research analysts have commented on CTLT shares. Zacks Investment Research lowered Catalent from a “hold” rating to a “strong sell” rating in a research note on Monday, August 15th. Bank of America Corp. upgraded Catalent from a “neutral” rating to a “buy” rating and set a $28.00 price objective for the company in a research note on Monday, June 20th. They noted that the move was a valuation call. TheStreet upgraded Catalent from a “sell” rating to a “hold” rating in a research note on Wednesday, August 17th. Jefferies Group reiterated a “hold” rating and set a $25.00 price objective on shares of Catalent in a research note on Friday, June 10th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and set a $30.00 price objective (down from $30.50) on shares of Catalent in a research note on Tuesday, August 30th.
In other news, major shareholder Blackstone Management Associat sold 17,100,705 shares of the business’s stock in a transaction that occurred on Friday, September 9th. The stock was sold at an average price of $23.58, for a total transaction of $403,234,623.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Several hedge funds and other institutional investors have recently modified their holdings of CTLT. GW&K Investment Management LLC boosted its position in shares of Catalent by 2.7% in the second quarter. GW&K Investment Management LLC now owns 1,755,362 shares of the company’s stock valued at $40,356,000 after buying an additional 46,305 shares in the last quarter. Eagle Asset Management Inc. boosted its position in Catalent by 21.1% in the second quarter. Eagle Asset Management Inc. now owns 112,315 shares of the company’s stock worth $2,582,000 after buying an additional 19,579 shares in the last quarter. Acadian Asset Management LLC boosted its position in Catalent by 46,852.1% in the second quarter. Acadian Asset Management LLC now owns 316,927 shares of the company’s stock worth $7,285,000 after buying an additional 316,252 shares in the last quarter. LS Investment Advisors LLC boosted its position in Catalent by 85.2% in the second quarter. LS Investment Advisors LLC now owns 7,131 shares of the company’s stock worth $164,000 after buying an additional 3,280 shares in the last quarter. Finally, Louisiana State Employees Retirement System boosted its position in Catalent by 4.4% in the second quarter. Louisiana State Employees Retirement System now owns 28,500 shares of the company’s stock worth $655,000 after buying an additional 1,200 shares in the last quarter.
Shares of Catalent (NASDAQ:CTLT) traded up 0.43% during midday trading on Tuesday, hitting $25.94. The stock had a trading volume of 369,903 shares. The firm has a market cap of $3.24 billion and a price-to-earnings ratio of 29.15. Catalent has a 52-week low of $18.92 and a 52-week high of $32.24. The firm’s 50 day moving average price is $25.26 and its 200 day moving average price is $25.67.
Catalent (NASDAQ:CTLT) last posted its quarterly earnings data on Monday, August 29th. The company reported $0.52 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.53 by $0.01. The business earned $532.20 million during the quarter. During the same quarter last year, the company posted $0.61 earnings per share. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. On average, equities research analysts expect that Catalent will post $1.40 earnings per share for the current year.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Stock Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related stocks with our FREE daily email newsletter.